GenEdit: Sarepta and GenEdit partner to develop neuromuscular disease therapies
Though the deal, Sarepta will gain exclusive option rights for licensing polymer nanoparticles developed by GenEdit. The post Sarepta and GenEdit partner to develop neuromuscular disease therapies appeared first on Pharmaceutical Technology.
Read full article »
GenEdit is a California-based biotechnology company that develops and commercializes curative therapies for the treatment of genetic diseases.
Read more